Emboline, Inc. Secures $20 Million in Growth Capital from Trinity Capital Inc. to Support Commercialization of the Emboliner® Embolic Protection System to Minimize Stroke Risk From TAVR

Emboline closed $20 million in growth capital from Trinity Capital (Nasdaq: TRIN) to fund commercialization of the Emboliner® Embolic Protection System and further platform development.

Rhea-AI Summary

Emboline closed $20 million in growth capital from Trinity Capital (Nasdaq: TRIN) to fund commercialization of the Emboliner® Embolic Protection System and further platform development. The company completed enrollment in its IDE trial (NCT05684146) and will present results on March 29, 2026 at ACC.

Financing will support U.S. and European commercial launch preparations and ongoing regulatory submissions; the Emboliner device remains investigational and is not available for commercial sale.

Positive

• $20M growth capital secured from Trinity Capital
• Completed enrollment in IDE trial NCT05684146
• Planned presentation of trial results on March 29, 2026 at ACC
• Company preparing for U.S. and Europe commercial launch later in 2026

Negative

• Emboliner device is investigational and not yet approved for commercial sale
• Regulatory submissions remain pending, creating near-term approval uncertainty

Argus Mar 11 session

-0.60% close to close Open Argus

Details

News Market Reaction – TRIN

In the Mar 11 session, TRIN declined 0.60%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Trinity Capital’s continued deployment of growth capital, adding a $20 ...

Analysis

This announcement highlights Trinity Capital’s continued deployment of growth capital, adding a $20 million facility to Emboline to support commercialization of its Emboliner embolic protection system. It deepens exposure to structural heart and transcatheter procedures, with PROTECT H2H IDE trial results slated for March 29, 2026. In context of recent UK growth deals and strong 2025 results, investors may watch portfolio performance, clinical milestones at borrowers, and credit quality metrics in upcoming disclosures.

Key Figures

Growth capital financing: $20 million Trial presentation date: March 29, 2026 Capital deployed: More than $5.5 billion +2 more

Growth capital financing

$20 million

Debt financing from Trinity Capital to Emboline

Trial presentation date

March 29, 2026

PROTECT H2H IDE trial results at ACC Scientific Session

Capital deployed

More than $5.5 billion

Total capital Trinity Capital has deployed since 2008 (as of Dec 31, 2025)

Total investments

Over 463 investments

Number of investments Trinity Capital has made since inception

Inception year

2008

Year Trinity Capital began deploying capital

Historical Context

5 past events · Latest: Feb 26

5 events

1. Feb 26

   Growth capital deal

   24h Move

   -1.3%

   Committed $50M growth capital to Dwelly to scale UK marketplace.

2. Feb 25

   Earnings results

   24h Move

   +2.5%

   Reported record 2025 income of $293.7M and NII of $144.1M.

3. Feb 3

   Earnings preview

   24h Move

   +0.5%

   Issued positive preliminary Q4 2025 NII and NAV ranges with low non‑accruals.

4. Feb 2

   Growth capital deal

   24h Move

   -2.9%

   Committed £25M to Motorway to support UK expansion and scaling.

5. Jan 28

   Credit rating update

   24h Move

   +0.5%

   Morningstar DBRS confirmed investment grade BBB (low) and raised trend.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

investigational device exemption (ide), embolic protection system, embolic debris, ischemic, +3 more

7 terms

investigational device exemption (ide) regulatory

"completed enrollment in the PROTECT H2H investigational device exemption (IDE) clinical trial"

An investigational device exemption (IDE) is a regulatory permission that allows a medical device to be used in clinical studies so companies can gather safety and effectiveness data before full market approval. For investors, an IDE is a key milestone because it lets a company test real-world performance and move toward commercial clearance or approval—much like a trial run that, if successful, can unlock larger revenue opportunities and reduce regulatory risk.

embolic protection system medical

"the Emboliner® Embolic Protection System is designed to provide full cerebral"

A device used during certain heart and blood vessel procedures that acts like a tiny filter or net to catch debris and clots that might break loose and travel to the brain or other organs. Investors care because these systems can lower the risk of costly complications, influence which procedures doctors choose, affect hospital costs and reimbursement, and therefore impact sales, adoption rates and regulatory scrutiny for companies that make them.

embolic debris medical

"by capturing and removing embolic debris released during transcatheter heart procedures"

Particles of tissue, blood clot, or other material that become loose and enter the bloodstream during medical procedures or from disease, then travel and can block small blood vessels—imagine pebbles carried by a stream that can jam narrow channels. Investors care because these particles drive safety risks like stroke, influence regulatory approval and labeling, and can create demand for protective technologies or lead to liability and slower adoption, all of which affect a medical device or treatment’s market value.

ischemic medical

"focused on reducing stroke and ischemic damage during structural heart procedures"

Ischemic describes a medical condition in which a tissue or organ is damaged because it receives too little blood and oxygen, often due to a blocked or narrowed vessel. For investors, ischemic conditions matter because they drive demand for treatments, diagnostics and medical devices, affect clinical trial outcomes and regulatory decisions, and can influence healthcare spending and company revenue in related sectors — like a garden hose pinched off, starving plants downstream.

structural heart procedures medical

"ischemic damage during structural heart procedures such as transcatheter aortic"

Structural heart procedures are medical interventions that repair or replace the heart’s internal parts—most commonly valves or supporting tissue—using either open surgery or less-invasive, catheter-based techniques threaded through blood vessels. For investors, these procedures indicate demand for durable medical devices, hospital capacity and reimbursement policies; like upgrading an aging building’s pumps and pipes, wider adoption and better outcomes can boost device makers’ sales and healthcare spending, while complications or regulatory setbacks create financial and clinical risk.

transcatheter cardiovascular procedures medical

"reduce embolic complications during transcatheter cardiovascular procedures."

Transcatheter cardiovascular procedures are medical treatments performed by threading a thin, flexible tube (catheter) through a small entry point in the skin and blood vessels to treat heart or blood vessel problems—for example, repairing or replacing valves, opening blocked arteries, or closing abnormal openings. Like fixing a valve through a pipe rather than tearing open the whole wall, these less-invasive procedures shorten hospital stays, lower complication risk and drive demand for specialized devices, hospitals and insurers, which matters to investors tracking healthcare technology and procedure volumes.

late-breaking clinical trial medical

"will be presented in a Late-Breaking Clinical Trial session on March 29, 2026"

A late-breaking clinical trial is newly released, high-impact study data that is shared quickly—often at a medical conference or in a press release—because the results are considered urgent or surprising. For investors, these announcements can change a drug’s outlook overnight, like a sudden weather report that shifts travel plans: they may affect a company’s valuation, regulatory pathway, and near-term stock movement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SANTA CRUZ, Calif., March 11, 2026 /PRNewswire/ -- Emboline, Inc., a privately held medical technology company focused on reducing stroke and ischemic damage during structural heart procedures such as transcatheter aortic valve replacement (TAVR), today announced it has closed $20 Million in growth capital from Trinity Capital, a leading international alternative asset manager.

Emboline recently completed enrollment in the PROTECT H2H investigational device exemption (IDE) clinical trial (NCT05684146), a prospective randomized study evaluating the Emboliner® Embolic Protection System. The funding will support Emboline's upcoming commercial launch activities and continued development of its embolic protection technology platform.

The Emboliner® Embolic Protection System is designed to provide full cerebral and systemic embolic protection by capturing and removing embolic debris released during transcatheter heart procedures. Emboline also holds an extensive intellectual property portfolio related to aortic embolic protection technologies, including full-body embolic filtration and aortic deflection approaches.

Results from the completed IDE clinical study will be presented in a Late-Breaking Clinical Trial session on March 29, 2026, at the American College of Cardiology Annual Scientific Session in New Orleans, Louisiana.

"Emboline's embolic filtering technology is designed with the goal of giving interventional cardiologists greater confidence when performing complex structural heart procedures while helping reduce the risk of stroke and other embolic complications," said Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital. "We are pleased to support Emboline during this important stage as the company prepares to bring its technology to physicians and patients worldwide."

"We are excited to partner with Trinity Capital at a pivotal moment for Emboline," said Scott Russell, President and CEO of Emboline. "With the completion of our IDE clinical trial and regulatory submissions ahead, this financing positions us to prepare for commercial launch in the United States and Europe later this year. Our goal is to provide physicians with a comprehensive embolic protection solution that helps reduce stroke and ischemic injury during transcatheter procedures."

With this financing, Emboline will advance preparations for the commercial introduction of the Emboliner® Embolic Protection System while continuing development of additional technologies designed to reduce embolic risk during structural heart interventions.

About Trinity Capital Inc.

Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences. As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than $5.5 billion across over 463 investments since inception in 2008 (as of December 31, 2025). Headquartered in Phoenix, Arizona, Trinity Capital's dedicated team is strategically located across the United States and Europe. For more information on Trinity Capital, please visit trinitycapital.com and stay connected to the latest activity via LinkedIn and X (@trincapital).

About Emboline

Emboline, Inc. is a privately held medical technology company based in Santa Cruz, California, focused on developing technologies designed to reduce embolic complications during transcatheter cardiovascular procedures.

The company's lead product, the Emboliner® Embolic Protection System, is designed to provide full cerebral and systemic embolic protection by capturing and removing debris that may be released during structural heart interventions and that could otherwise travel to the brain and other vital organs.

For more information, visit emboline.com.

The Emboliner® device is currently investigational and is not available for commercial sale.

Media Contact: media@emboline.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/emboline-inc-secures-20-million-in-growth-capital-from-trinity-capital-inc-to-support-commercialization-of-the-emboliner-embolic-protection-system-to-minimize-stroke-risk-from-tavr-302710533.html

SOURCE Emboline, Inc.

FAQ

What did Emboline announce about funding from Trinity Capital (TRIN) on March 11, 2026?

Emboline secured $20 million in growth capital from Trinity Capital. According to Emboline, the financing will support commercial launch preparations and continued development of its embolic protection platform.

What is the regulatory status of the Emboliner® Embolic Protection System (Emboline)?

The Emboliner device is currently investigational and not available for commercial sale. According to Emboline, regulatory submissions are underway as the company prepares for U.S. and European launch later in 2026.

When and where will Emboline present results from the IDE trial (NCT05684146)?

Emboline will present IDE trial results on March 29, 2026 during a Late-Breaking Clinical Trial session at the American College of Cardiology. According to Emboline, the presentation will be in New Orleans, Louisiana.

How will the $20M financing affect Emboline's commercialization plans for the Emboliner?

The financing is intended to fund commercial launch preparations and platform development. According to Emboline, the capital positions the company to prepare for U.S. and European commercial introductions later in 2026.

What clinical evidence supports the Emboliner device ahead of commercial launch?

Emboline completed enrollment in a prospective randomized IDE study (NCT05684146). According to Emboline, results from that study will be presented at ACC on March 29, 2026 as a Late-Breaking Clinical Trial.